CABA (Cabaletta Bio) Other Operating Expense: $-0.00 Mil (TTM As of Mar. 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $2.98
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Other Operating Expense?

Cabaletta Bio CABA -4.56% 34 Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Cabaletta Bio's Other Operating Expense for the three months ended in Mar. 2026 was $-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.

Cabaletta Bio's quarterly Other Operating Expense declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Cabaletta Bio's annual Other Operating Expense increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Cabaletta Bio Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Other Operating Expense Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 -0.00
CABA
34GF Score
Cabaletta Bio Inc CABA
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.00 Mil mean?
Cabaletta Bio (CABA) has a Other Operating Expense of $-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Cabaletta Bio and its competitors.
Is Cabaletta Bio's Other Operating Expense too high?
Cabaletta Bio's current Other Operating Expense is $-0.00 Mil. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Other Operating Expense compare to RZLT and CCCC?
Cabaletta Bio's Other Operating Expense of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Cabaletta Bio and its competitors. Cabaletta Bio's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Other Operating Expense of $-0.00 Mil. The current Other Operating Expense is $-0.00 Mil. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price